{'fraction_non_alphanumeric': 0.024720423778693348, 'fraction_numerical': 0.020600353148911125, 'mean_word_length': 5.367041198501872, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prognosis and clinical characteristics of colorectal cancer patients with KRAS gene mutation: a 5-year follow-up study.

To investigate the correlation of KRAS gene mutation and surgery for clinical characteristics and prognosis in patients with colorectal cancer under a 5-year follow-up, clinical data of 277 patients with colorectal cancer treated from January 2010 to December 2010 were collected. Patients with KRAS gene mutation were detected by direct sequencing and followed up for 5 years. KRAS gene mutation effect on clinicopathological factors and univariate and multivariate survival were analyzed. Among 277 patients, 109 (39.8%) indicated KRAS gene exon 2 mutation, among which 12 colon mutations showed the highest frequency. Furthermore, KRAS gene mutation was revealed to have a correlation with the expression of EGFR, primary tumor site, and multiple metastases of tumor. In follow-up, the average survival time of patients carrying wild-type and mutant-type was 49.9 months and 50.7 months, respectively. Univariate analysis showed that high TNM stage, advanced age, pulmonary metastasis, hepatic metastasis, and multiple metastases were associated with poor postoperative prognosis in patients with colorectal cancer. Multivariate analysis showed that advanced age and high TNM stage were independent risk factors for postoperative outcome in patients with colorectal cancer. The median OS in IV patients after surgery still reached 39.6 months, and some patients survived. In conclusion, KRAS gene mutation in colorectal cancer patients is closely related to EGFR expression, primary tumor site and multiple metastasis, and the survival time of advanced patients is prolonged.